These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24700981)

  • 21. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?
    Cohen-Kohler JC; Esmail LC; Cosio AP
    Global Health; 2007 Dec; 3():12. PubMed ID: 18062821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding drug access in Brazil: lessons for Latin America and Canada.
    Cohen JC
    Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global patent police block cost-reduction efforts.
    Kasper T
    GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
    Harvey K
    Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
    Vines T; Crow K; Faunce T
    J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis.
    Beall R; Kuhn R
    PLoS Med; 2012 Jan; 9(1):e1001154. PubMed ID: 22253577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
    't Hoen EFM; Boulet P; Baker BK
    J Pharm Policy Pract; 2017; 10():19. PubMed ID: 28670455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement.
    Chaves GC; Oliveira MA
    Bull World Health Organ; 2007 Jan; 85(1):49-56. PubMed ID: 17242758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. US files WTO complaints against Brazil over requirement for "local working" of patents.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2000; 5(4):28. PubMed ID: 11833162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.